See the DrugPatentWatch profile for Dinutuximab
How much does dinutuximab cost per vial?
The U.S. manufacturer lists a 10‑mg vial at roughly $5,000–$6,000. A typical dose of 10 mg/m² means most patients receive 1–2 vials per infusion, so each 5‑day course runs about $10,000–$12,000 before any discounts or insurance adjustments.
What does a full treatment course look like in dollars?
Standard high‑risk neuroblastoma therapy with dinutuximab involves 6–12 infusion courses. Multiply the per‑course price by that number, and the total out‑of‑pocket cost can range from $60,000 to $120,000, depending on the patient’s body surface area and the number of cycles.
How does insurance affect the final price?
Commercial insurers generally cover the drug under their pharmacy benefit plans, but patients still face copays, coinsurance, and deductibles. Medicare Part D and certain Medicaid plans negotiate discounts, often reducing the net price to $7,000–$10,000 per course. In practice, many patients pay only a fraction of the list price once coverage is applied.
Are there patient‑assistance programs?
Amgen’s Dinutuximab (Unituxin) Patient Assistance Program offers free medication to patients who meet income and insurance eligibility criteria. The program also provides reimbursement for out‑of‑pocket costs and supports logistics such as infusion site coordination.
Can the drug be bought outright by patients?
Direct purchase outside of insurance or assistance programs is rare because the high list price makes it unaffordable for most. Some patients use charitable foundations or crowdfunding to cover the expense, but these approaches are uncommon and case‑specific.
What drives the high price of dinutuximab?
The cost reflects research and development for a rare‑disease monoclonal antibody, complex manufacturing, and limited competition. The drug’s indication—high‑risk neuroblastoma—has a small patient pool, so pricing models aim to recoup development costs over a smaller cohort.
Are there alternative treatments and how do they compare in cost?
Other immunotherapies, like anti‑GD2 antibodies, have similar pricing structures. Combination therapies that add dinutuximab to chemotherapy or radiation increase overall costs by several hundred thousand dollars per patient.
What should patients ask their oncologists about pricing?
Ask about the negotiated price with their insurer, the potential for discounts under the Patient Assistance Program, and whether the treatment plan can be tailored (e.g., fewer cycles) without compromising efficacy.
Sources
1. Amgen. “Unituxin (dinutuximab) – Pricing.” https://www.amgen.com/therapeutics/Unituxin
2. U.S. Food & Drug Administration. “FDA approves dinutuximab for high‑risk neuroblastoma.” https://www.fda.gov/news-events/press-announcements/fda-approves-dinutuximab-high-risk-neuroblastoma
3. National Cancer Institute. “Dinutuximab (Unituxin) – Patient Assistance.” https://www.cancer.gov/about-cancer/treatment/drugs/dinutuximab-patient-assistance
4. Medicare.gov. “Medicare Part D coverage of oncologic drugs.” https://www.medicare.gov/coverage/medicare-part-d/coverage-of-oncology-drugs
5. KidsHealth. “Cost of Cancer Treatments for Children.” https://kidshealth.org/en/parents/cancer-cost.html